만성 콩판병(CKD) 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Chronic Kidney Disease (CKD) Drugs Market size is expected to reach USD 29.48 Billion in 2034 from USD 19.87 Billion (2025) growing at a CAGR of 4.48% during 2026-2034.

The global chronic kidney disease drugs market is expanding steadily due to the rising prevalence of kidney disorders worldwide. Factors such as increasing rates of diabetes, hypertension, and aging populations are contributing significantly to the growing incidence of chronic kidney disease. As CKD progresses gradually and requires long-term management, the demand for effective pharmaceutical therapies is increasing. Healthcare providers are focusing on early diagnosis and treatment to slow disease progression and reduce complications.

Pharmaceutical companies are investing heavily in research and development to introduce novel therapies targeting kidney function and related complications. New classes of drugs, including SGLT2 inhibitors and mineralocorticoid receptor antagonists, are showing promising results in slowing CKD progression. Additionally, the growing availability of combination therapies is improving patient outcomes. Governments and healthcare organizations are also implementing programs aimed at improving CKD awareness and treatment accessibility.

Looking ahead, the market is expected to witness significant innovation as biotechnology and precision medicine approaches advance. Increasing clinical trials for new kidney disease therapies will likely expand the treatment landscape. Moreover, improving healthcare infrastructure and expanding access to nephrology treatments in developing countries will contribute to long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• ACE Inhibitors
• Angiotensin-II Receptor Blockers
• Calcium Channel Blockers
• Beta Blockers
• Erythropoiesis-stimulating Agents (ESAs)
• Diuretics
• Others

By End-user

• Hospitals
• Specialty Clinics

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Pfizer Inc, Sanofi, GSK plc, Kissei Pharmaceutical Co Ltd, AbbVie Inc, Akebia Therapeutics Inc, AstraZeneca, Amgen Inc, Teva Pharmaceutical Industries Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. ACE Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Angiotensin-II Receptor Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Calcium Channel Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Erythropoiesis-stimulating Agents (ESAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Diuretics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET: BY END-USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-user
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By End-user
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By End-user
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By End-user
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By End-user
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By End-user
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 F. Hoffmann-La Roche Ltd
  • 8.2.2 Pfizer Inc
  • 8.2.3 Sanofi
  • 8.2.4 GSK Plc
  • 8.2.5 Kissei Pharmaceutical Co. Ltd
  • 8.2.6 AbbVie Inc
  • 8.2.7 Akebia Therapeutics Inc
  • 8.2.8 AstraZeneca
  • 8.2.9 Amgen Inc
  • 8.2.10 Teva Pharmaceutical Industries Ltd